Navigation Links
Alios BioPharma initiates Phase 1 clinical trial for respiratory syncytial virus infection
Date:5/30/2013

SOUTH SAN FRANCISCO, CA May 30, 2013 Alios BioPharma, Inc. today announced that it has begun oral dosing of ALS-8176 in a Phase 1 clinical trial. ALS-8176 is a structurally novel, anti-respiratory syncytial virus (RSV) nucleoside analog that is being developed for the treatment of acute RSV infection. It is the only known nucleoside analog currently in clinical development for the treatment of RSV. ALS-8176 demonstrates potent anti-viral activity across multiple strains of RSV in preclinical studies and represents an important step forward in the development of more effective treatments for this serious and often life threatening disease.

The randomized, double-blind, placebo-controlled, Phase 1 study of orally administered ALS-8176 will evaluate safety, tolerability, and pharmacokinetics of single ascending doses and multiple ascending doses in healthy volunteers. The trial will assess several dose levels in up to 90 healthy adults.

ALS-8176 was discovered following the optimization of screening hits obtained through testing the Alios proprietary nucleoside analog library against replicating RSV in cell culture. The compound acts by blocking replication through a classic chain-termination mechanism and inhibits all RSV strains tested.

Due to their high barrier to viral resistance, nucleoside analogs have become the backbone of antiviral therapy in many clinical settings including the treatment of human immunodeficiency virus (HIV), hepatitis B virus (HBV) and herpes simplex virus (HSV). More recently, emerging data suggest the pivotal role nucleoside analogs will play in the future treatment of chronic hepatitis C (HCV).

"Alios believes ALS-8176 has great potential to become an effective first-line antiviral therapy for RSV infection, a disease where few treatment options currently exist," said Lawrence M. Blatt, PhD, Chief Executive Officer. "The advancement of ALS-8176 for RSV, together with the recently reported positive clinical data with VX-135 (formerly ALS-2200, an anti-HCV nucleotide analog), demonstrates the broad capabilities of the Alios discovery platform. We are currently utilizing this platform to screen against several infectious diseases with high unmet medical needs."

Alios has built its drug discovery engine based on its core competencies in nucleoside synthetic chemistry, including prodrug chemistry, and a breadth and depth of virology expertise built over decades in the antiviral field. The Alios platform has been utilized to create a portfolio of antiviral drug candidates against multiple viruses including HCV, RSV, picornavirus (rhinovirus), and norovirus. In addition, the company is selectively pursuing non-nucleoside drug discovery in areas where combination regimens may be particularly useful.


'/>"/>

Contact: John Donovan
press@aliosbiopharma.com
650-635-5504
Alios BioPharma, Inc.
Source:Eurekalert

Related biology news :

1. Exclusive agreement to distribute Affinity Biosensors Archimedes system extends Malvern Instruments biopharma solutions
2. Discovery of a molecule that initiates maturation of mammalian eggs can lead to more IVF pregnancies
3. Carnegie Mellon neuroscientists discover new phase of synaptic development
4. Monoclonal Antibody with Xencors High ADCC Fc Technology Enters Phase 2 Study in B-cell Acute Lymphoblastic Leukemia
5. FDA approves Phase II of stem cell trial for ALS led by U-Ms Dr. Eva Feldman
6. In beef production, cow-calf phase contributes most greenhouse gases
7. F1000Research, the first Open Science publisher, launches following a successful beta testing phase
8. National Geographic unveils new phase of genographic project
9. King Richard III search in new phase after discovery has potential to rewrite history
10. Center for Clinical and Translational Science awards new pilot grants
11. Elseviers Maturitas publishes clinical guide on endometrial assessment in postmenopausal women
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/20/2017)... , July 20, 2017 Delta (NYSE: DAL ) ... any Delta aircraft at Reagan Washington National Airport (DCA). ... Delta launches biometrics to board ... Delta,s biometric boarding ... Club is now integrated into the boarding process to allow eligible ...
(Date:5/16/2017)... 16, 2017  Veratad Technologies, LLC ( www.veratad.com ), ... and identity verification solutions, announced today they will participate ... May 15 thru May 17, 2017, in ... Trade Center. Identity impacts the lives ... today,s quickly evolving digital world, defining identity is critical ...
(Date:4/18/2017)... SUNNYVALE, Calif. , April 18, 2017  Socionext Inc., a ... prototype of a media edge server, the M820, which features the ... face recognition software provided by Tera Probe, Inc., will be showcased ... and at the NAB show at the Las Vegas ... ...
Breaking Biology News(10 mins):
(Date:8/15/2017)... NC (PRWEB) , ... August 15, 2017 , ... ... 2017, celebrating 10 years of successes helping medical technology companies and inventors develop and ... to a renowned full-service national engineering firm with a portfolio of clients in the ...
(Date:8/15/2017)... ... August 15, 2017 , ... Kenall, a leader ... designed to stay tightly sealed and perform efficiently for years. The downlights are ... listings just aren't enough, such as: hospitals; behavioral health facilities; cleanrooms; containment areas; ...
(Date:8/14/2017)... ... August 14, 2017 , ... Every year, ... researchers in the antibody community have recently come together to address this antibody ... the laboratory. , The team at Thermo Fisher Scientific ...
(Date:8/11/2017)... ... August 11, 2017 , ... A staple in the community ... that will incorporate important key elements including a new digital marketing strategy and updated ... supported them, Bill Miller has partnered with the South Texas Blood & Tissue Center ...
Breaking Biology Technology: